BUND FINANCE › Stocks › DXCM
DexCom, Inc. (DXCM)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -4.65% below its 50-day average.
- It is +6.60% above its 200-day average (long-term uptrend).
- It sits at 65% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$2.4B | US$2.9B | US$3.6B | US$4.0B | US$4.7B |
| Net income | US$216.9M | US$341.2M | US$541.5M | US$576.2M | US$836.3M |
| EPS (diluted) | 0.53 | 0.82 | 1.30 | 1.42 | 2.09 |
| Gross margin | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Net margin | 8.9% | 11.7% | 15.0% | 14.3% | 17.9% |
| Free cash flow | US$53.3M | US$304.7M | US$511.9M | US$630.7M | US$1.1B |
| Total debt | US$2.2B | US$2.1B | US$2.6B | US$2.6B | US$1.4B |
| Cash | US$1.1B | US$642.3M | US$566.3M | US$606.1M | US$917.7M |
Compound annual growth: revenue 17.5% · net income 40.1% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 31.5x | 107.8x | 26.4x |
| EV / EBITDA | 19.0x | 66.1x | 16.3x |
| Operating margin | 24.0% | — | 3.6% |
| Net margin | 19.4% | — | -0.0% |
| Debt / equity | 1.46 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring plat…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice